 |
27 Diseases |  |
27 Trials |
|
27 Trials |  |
307 News |  |
| «12345678 |
- |||||||||| Lumitin (conbercept) / Chengdu Kanghong Pharma
New P3 trial: Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-1) (clinicaltrials.gov) - Jul 5, 2018
P3, N=1140, Not yet recruiting, Sponsor: Chengdu Kanghong Biotech Co.,Ltd.
- | Lumitin (conbercept) / Chengdu Kanghong Pharma
New P1 trial: Safety and Effectiveness of Intravitreal Conbercept for Exudative Circumscribed Choroidal Haemangioma (clinicaltrials.gov) - Jun 27, 2018
P1, N=50, Recruiting, Sponsor: Sun Yat-sen University
- | Lumitin (conbercept) / Chengdu Kanghong Pharma
New P1 trial: Intravitreal Conbercept After Vitrectomy (clinicaltrials.gov) - Feb 8, 2018
P1, N=50, Active, not recruiting, Sponsor: Tianjin Medical University Eye Hospital
- | Lumitin (conbercept) / Chengdu Kanghong Pharma
Enrollment open, Trial initiation date: Conbercept vs Panretinal Photocoagulation for the Management of Proliferative Diabetic Retinopathy (clinicaltrials.gov) - Oct 13, 2017
P=N/A, N=226, Enrolling by invitation, Sponsor: Sun Yat-sen University
Active, not recruiting --> Enrolling by invitation | Initiation date: Sep 2016 --> Oct 2017
- ||||| Lumitin (conbercept) / Chengdu Kanghong Pharma
New P4 trial: Phase IV Clinical Trial (STAR Study) Extension Study of Conbercept Ophthalmic Injection for Treatment of Polypoid Choroidal Vasculopathy (clinicaltrials.gov) - Aug 8, 2017
P4, N=200, Recruiting, Sponsor: Chengdu Kanghong Biotech Co.,Ltd.
- |||||||||| Lumitin (conbercept) / Chengdu Kanghong Pharma
New P3 trial: CRVO: Conbercept Ophthalmic Injection for Patients of Central Retinal Vein Occlusion (clinicaltrials.gov) - Jul 20, 2017
P3, N=237, Recruiting, Sponsor: Chengdu Kanghong Biotech Co.,Ltd.
- | Lumitin (conbercept) / Chengdu Kanghong Pharma
New trial: The Effect of Conbercept Injection Through Different Routes for Neovascular Glaucoma (clinicaltrials.gov) - May 15, 2017
P=N/A, N=30, Recruiting, Sponsor: Second Affiliated Hospital of Xi'an Jiaotong University
- | Lumitin (conbercept) / Chengdu Kanghong Pharma
Biomarker, New trial: Pharmacogenomic Study on Anti-VEGF Medicine in Treatment of Macular Neovascular Diseases (clinicaltrials.gov) - Apr 25, 2017
P=N/A, N=5000, Recruiting, Sponsor: Xun Xu
- ||| Lumitin (conbercept) / Chengdu Kanghong Pharma
New trial: Safety Evaluation of China Patients: Long-term Treatment Outcome of Conbercept Ophthalmic Injection in Real Word?STONE? (clinicaltrials.gov) - Feb 16, 2017
P=N/A, N=4000, Recruiting, Sponsor: Chengdu Kanghong Biotech Co.,Ltd.
- Lumitin (conbercept) / Chengdu Kanghong Pharma, Visudyne (verteporfin) / Novartis
Enrollment open, Combination therapy: Initial Versus Delayed PDT Combination With Conbercept in PCV (clinicaltrials.gov) - Jan 4, 2017
P4, N=80, Recruiting, Sponsor: The Eye Hospital of Wenzhou Medical University
Active, not recruiting --> Enrolling by invitation | Initiation date: Sep 2016 --> Oct 2017 Not yet recruiting --> Recruiting
- Lumitin (conbercept) / Chengdu Kanghong Pharma, Visudyne (verteporfin) / Novartis
Trial initiation date, Trial primary completion date, Combination therapy: Initial Versus Delayed PDT Combination With Conbercept in PCV (clinicaltrials.gov) - Dec 15, 2016
P4, N=80, Not yet recruiting, Sponsor: The Eye Hospital of Wenzhou Medical University
Not yet recruiting --> Recruiting Initiation date: Jul 2016 --> Jan 2017 | Trial primary completion date: Jul 2017 --> Jan 2018
- Lumitin (conbercept) / Chengdu Kanghong Pharma
New P2 trial: Conbercept in Choroidal Neovascularization Secondary to Uveitis (clinicaltrials.gov) - Oct 16, 2016
P2, N=40, Not yet recruiting, Sponsor: Chongqing Medical University
- Lumitin (conbercept) / Chengdu Kanghong Pharma
New trial: Conbercept vs Panretinal Photocoagulation for the Management of Proliferative Diabetic Retinopathy (clinicaltrials.gov) - Sep 22, 2016
P=N/A, N=226, Active, not recruiting, Sponsor: Sun Yat-sen University
- Lumitin (conbercept) / Chengdu Kanghong Pharma
New P2 trial: Intravitreal Conbercept for Idiopathic Choroidal Neovascularization (clinicaltrials.gov) - Aug 5, 2016
P2, N=50, Recruiting, Sponsor: Jiao Mingfei
- | Lucentis (ranibizumab) / Roche, Novartis
Trial completion, Head-to-Head: RELIANCE: Head to Head Study of Anti-VEGF Treatment. (clinicaltrials.gov) - Aug 2, 2016
P4, N=12, Completed, Sponsor: Novartis Pharmaceuticals
Initiation date: Jul 2016 --> Jan 2017 | Trial primary completion date: Jul 2017 --> Jan 2018 Recruiting --> Completed
- | Lumitin (conbercept) / Chengdu Kanghong Pharma, Visudyne (verteporfin) / Novartis
New P4 trial, Combination therapy: Initial Versus Delayed PDT Combination With Conbercept in PCV (clinicaltrials.gov) - Jul 1, 2016
P4, N=80, Not yet recruiting, Sponsor: The Eye Hospital of Wenzhou Medical University
- Lumitin (conbercept) / Chengdu Kanghong Pharma
New P4 trial: Conbercept Injection in Treatment of Severe Proliferative Diabetic Retinopathy (clinicaltrials.gov) - Jun 28, 2016
P4, N=30, Recruiting, Sponsor: Ruijin Hospital
- | Lumitin (conbercept) / Chengdu Kanghong Pharma
New P4 trial: Efficacy and Safety of "Treat-and-Extend" Regimen Versus "Pro Re Nata" of Conbercept in Age-related Macular Degeneration (clinicaltrials.gov) - Jun 16, 2016
P4, N=120, Not yet recruiting, Sponsor: Xiaodong Sun
- | Lucentis (ranibizumab) / Roche, Novartis
Enrollment open, Head-to-Head: RELIANCE: Head to Head Study of Anti-VEGF Treatment. (clinicaltrials.gov) - May 5, 2016
P4, N=12, Recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed Not yet recruiting --> Recruiting
- | Lucentis (ranibizumab) / Roche, Novartis
New P4 trial, Head-to-Head: RELIANCE: Head to Head Study of Anti-VEGF Treatment. (clinicaltrials.gov) - Oct 22, 2015
P4, N=12, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- |||||| Lumitin (conbercept) / Chengdu Kanghong Pharma
Enrollment open: Safety and Efficacy Study of Conbercept in Diabetic Macular Edema (DME) (Sailing) (clinicaltrials.gov) - Jun 9, 2015
P3, N=248, Recruiting, Sponsor: Chengdu Kanghong Biotech Co.,Ltd.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||||||||| Lumitin (conbercept) / Chengdu Kanghong Pharma
New P3 trial: Safety and Efficacy Study of Conbercept in Diabetic Macular Edema (DME) (Sailing) (clinicaltrials.gov) - Jul 18, 2014
P3, N=248, Not yet recruiting, Sponsor: Chengdu Kanghong Biotech Co.,Ltd.
- | Lumitin (conbercept) / Chengdu Kanghong Pharma
New P2 trial: An Open, Single-center, Safety and Efficacy Study of Conbercept in Patients With Very Low Vision Secondary to Wet Age-related Macular Degeneration (wAMD) (clinicaltrials.gov) - Mar 26, 2014
P2, N=30, Active, not recruiting, Sponsor: Chengdu Kanghong Biotech Co.,Ltd.
- ||| Lumitin (conbercept) / Chengdu Kanghong Pharma
Enrollment closed: FALCON: Efficacy and Safety of Conbercept in Macular Edema Secondary to Retinal Vein Occlusion (clinicaltrials.gov) - Mar 24, 2014
P2, N=60, Active, not recruiting, Sponsor: Chengdu Kanghong Biotech Co.,Ltd.
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||||| Lumitin (conbercept) / Chengdu Kanghong Pharma
Enrollment closed: SHINY: A Randomized, Double-blind, Multicenter, Sham-controlled, Safety and Efficacy Study of Conbercept in Patients With mCNV (clinicaltrials.gov) - Mar 20, 2014
P3, N=176, Active, not recruiting, Sponsor: Chengdu Kanghong Biotech Co.,Ltd.
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||||||| Lumitin (conbercept) / Chengdu Kanghong Pharma
Trial completion: A Randomized, Double-masked, Multicenter,Sham-controlled, Safety and Efficacy Study of KH902 in Patients With Wet AMD (clinicaltrials.gov) - Mar 20, 2014
P3, N=125, Completed, Sponsor: Chengdu Kanghong Biotech Co.,Ltd.
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- |||||||||| Lumitin (conbercept) / Chengdu Kanghong Pharma
New P3 trial: SHINY: A Randomized, Double-blind, Multicenter, Sham-controlled, Safety and Efficacy Study of Conbercept in Patients With mCNV (clinicaltrials.gov) - Mar 10, 2013
P3, N=176, Active, not recruiting, Sponsor: Chengdu Kanghong Biotech Co.,Ltd.
- ||||| Lumitin (conbercept) / Chengdu Kanghong Pharma
New P2 trial: FALCON: Efficacy and Safety of Conbercept in Macular Edema Secondary to Retinal Vein Occlusion (clinicaltrials.gov) - Mar 10, 2013
P2, N=60, Active, not recruiting, Sponsor: Chengdu Kanghong Biotech Co.,Ltd.
- | Lumitin (conbercept) / Chengdu Kanghong Pharma
Trial completion: Frontier-1: Safety and Efficacy by Multiple Injection of KH902 in Patients With Diabetic Macular Edema (DME) (clinicaltrials.gov) - Feb 27, 2013
P1/2, N=20, Completed, Sponsor: Chengdu Kanghong Biotech Co.,Ltd.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||| Lumitin (conbercept) / Chengdu Kanghong Pharma
Trial completion: AURORA: A Randomized, Double-masked, Multicenter, Controlled Study of Intravitreal KH902 in Patients With Neovascular AMD (clinicaltrials.gov) - Feb 27, 2013
P2, N=122, Completed, Sponsor: Chengdu Kanghong Biotech Co.,Ltd.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||||||||| Lumitin (conbercept) / Chengdu Kanghong Pharma
New P3 trial: A Randomized, Double-masked, Multicenter,Sham-controlled, Safety and Efficacy Study of KH902 in Patients With Wet AMD (clinicaltrials.gov) - Sep 18, 2011
P3, N=125, Completed, Sponsor: Chengdu Kanghong Biotech Co.,Ltd.